RxDoctor Payments Data

Crystal Walls

Family · Cumberland, MDNPI 1396222998

Payments from drug & device makers

$2,115in general payments, 2019–2025

Across 137 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$703
  • Indivior Inc.$368
  • Novo Nordisk$182
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$151
  • Lilly USA, LLC$128
  • USWM, LLC$115
  • plus $469 from 10 others

What the payments were for

  • Food & beverage$2,09499%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,115 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$85,158
Medicare patients
140
Services billed
1,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide147$154,771
OzempicSemaglutide71$66,351
VraylarCariprazine Hcl28$38,251
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl260$19,348
EliquisApixaban24$14,725
LinzessLinaclotide16$8,026
SuboxoneBuprenorphine Hcl/Naloxone Hcl19$7,675
VyvanseLisdexamfetamine Dimesylate14$7,491
ZubsolvBuprenorphine Hcl/Naloxone Hcl34$7,381
XareltoRivaroxaban11$5,715
Naloxone Hcl31$4,430
Buprenorphine Hcl33$1,253
Vilazodone Hcl12$1,131
Lisinopril78$844
Celecoxib23$790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$128$154,771147 claims
Novo NordiskOzempic$182$66,35171 claims
AbbVieVraylar, Linzess$703$46,27744 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl$21$20,601293 claims
PfizerEliquis$21$14,72524 claims
Indivior Inc.Suboxone$368$7,67519 claims
Orexo US, Inc.Zubsolv$98$7,38134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Cumberland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →